Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — FY2014 Earnings Presentation
18 slides from Monash Ivf's earnings presentation, Aug 28, 2014
Slide 1: FY2014 Results Presentation
FY2014 RESULTS PRESENTATION
Slide 2: Disclaimer
DISCLAIMER The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purpo
Slide 3: Agenda
AGENDA 1 FY2014 Result Highlights 2 FY2014 Result Detail 3 Strategy and Outlook A Appendix 3
Slide 4: FY2014 Result Highlights
) MONASH IVF GROUP FY2014 RESULT HIGHLIGHTS
Slide 5: FY2014 Financial Highlights
FY2014 FINANCIAL HIGHLIGHTS Record revenue and earnings growth in FY2014 and ahead of prospectus forecasts Vs. Vs. Pro Forma FY2014 Pro Forma Pro Forma FY2013 Forecast Pro Forma Actual Actual Pro Forma (Prospectus) Forecast Actual (Prospectus) $ million FY2014 FY2013 FY2014 $’M $’M $’M $’M $’M Reven
Slide 6: FY2014 Financial Highlights (Statutory)
FY2014 FINANCIAL HIGHLIGHTS Record revenue and earnings growth in FY2014 and ahead of prospectus forecasts Statutory Statutory Statutory Actual Prospectus Actual $ million FY2014 FY2014 FY2013 $’M $’M $’M Revenue 114.0 112.1 96.6 EBITDA 24.5 25.2 36.7 EBIT 21.6 22.4 32.1 NPAT 4.9 4.9 (12.7) Revenue
Slide 7: Monash Group's Growth Pillars
MONASH GROUP’S GROWTH PILLARS Leader in a growing industry with multiple competitive advantages 1 1 Leader in science and innovation •Provide patients with the highest success rates and effective treatment – FY2014 success rate of 32% vs industry average of 25%(1) •Continue to invest in advances in
Slide 8: FY2014 Operational Highlights
FY2014 OPERATIONAL HIGHLIGHTS Delivering on strategic initiatives Leader in science and innovation Patient success – delivered industry leading success rates Diagnostic and ancillary services – continued strong patient demand for PGS and NIPT offering Industry leader in Australia with significant
Slide 9: FY2014 Result Detail
) MONASH IVF GROUP FY2014 RESULT DETAIL
Slide 10: Patient Treatment Growth
PATIENT TREATMENT GROWTH Strong patient treatment growth reflecting continued steady organic growth and initial contribution of acquisitions Patient Treatments Year-on-Year Analysis Prospectus • Australian business up 9.5% FY2014 FY2013 Change FY2014 – Organic growth of 4.2% (ex acquisitions) Monash
Slide 11: Summary Income Statement
SUMMARY INCOME STATEMENT Continued revenue and earnings growth Year-on-Year Analysis Pro Forma Income Statement • Revenue up 18.4% driven by: Prospectus $ million FY2014 FY2013 Change FY2014 – 13.6% growth in Patient Treatments (combination of organic growth, Total Revenue 114.0 96.3 18.4% 112.1 acq
Slide 12: Cash Flows
CASH FLOWS Continued strong cash flow generation Pro Forma Cash Flow Statement Year on Year analysis Prospectus $ million FY2014 FY2013 Change FY2014 • Positive cash flow contribution from working capital as business continues to grow EBITDA 39.7 34.9 13.8% 38.8 • Increase in capex as a result of ro
Slide 13: Balance Sheet
BALANCE SHEET Balance Sheet Statutory Pro Forma $ million • Strong cash flow generation reduced closing net debt to $86.7 June 2014 December 2013 million at 30 June 2014 Cash and cash equivalents 8.8 (3.4) – Represents 2.2 x FY2014 pro-forma EBITDA Trade and other receivables 3.0 5.0 – Strong cash f
Slide 14: Strategy and Outlook
) MONASH IVF GROUP STRATEGY AND OUTLOOK
Slide 15: Strategy and Outlook
STRATEGY AND OUTLOOK Science, • Continue to develop industry leading science and technology technology & • Deliver patients with clinically superior services and increase market penetration patient success • Promote Monash Group’s scientific and clinical excellence with potential patients • MyIVF cl
Slide 16: Questions
QUESTIONS 16
Slide 17: Appendix
) MONASH IVF GROUP APPENDIX
Slide 18: Pro Forma – Statutory Profit & Loss Reconciliation
PRO FORMA – STATUTORY PROFIT & LOSS RECONCILIATION $ million Notes NPAT EBITDA $ million Notes NPAT EBITDA FY2014 Statutory profit / (loss) incl. FY2013 Statutory profit / (loss) incl. 4.9 24.5 (13.3) 35.1 public company costs public company costs IPO transaction costs expensed (1) 12.3 12.3 IPO tra